Ludlow Capital Adds Sinovac to China Small Cap Index
Wednesday July 19, 11:39 am ET
BEIJING, July 19 /Xinhua-PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex:
SVA -
News), a leading provider of biopharmaceutical products in China, announced today that it has been added as a component of the Ludlow China SmallCap Index. Gerry Salazar, President of the Ludlow SmallCap China Index commented, "The launch of the Ludlow China SmallCap Index now gives both institutional and individual investors a gauge to track the overall performance of small cap Chinese equities."
Mr. Weidong Yin, Chief Executive Officer of Sinovac, remarked, "We are honored to be recognized by Ludlow Capital as one of the leading China-based small cap companies traded in the U.S."
In 2006, Sinovac will continue to focus its marketing efforts on domestic sales, particularly its inactivated hepatitis A vaccine, Healive. Sinovac is increasing the production and sales of Healive to capture a larger market share in anticipation of live attenuated hepatitis A vaccines exclusion in China by the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP), effective January 1, 2006. Sinovac also expects to begin sales of its proprietary influenza vaccine, Anflu, in the product's first full flu sales season.
About Ludlow China SmallCap Index
The Ludlow Small Cap China Index is a basket of some of the top US traded OTC and small cap Chinese stocks. The Index provides institutional and individual investors a gauge for tracking the day-to-day performance of small cap Chinese stocks in a diversified basket. The index is designed for investors who have a long-term bullish outlook on China's emerging small cap market. The Ludlow China Index is owned and operated by Ludlow China Fund, Inc., based in New York City. For more information on the Ludlow China SmallCap Index and components visit
www.ludlowcapital.com/indices/
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
CONTACT:
Craig H. Bird
Segue Investor Relations
Phone: (215) 885 - 4981
Fax: (215) 885 - 4982
Contact: Ludlow China Index
Gerry Salazar
Tel.: +1-718-855-8451
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.
EN
